Actively Recruiting

Age: 18Years +
All Genders
NCT03611816

Biological Bank for Atrial Fibrillation and Stroke

Led by Hospices Civils de Lyon · Updated on 2026-04-17

1000

Participants Needed

5

Research Sites

782 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years. According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted. The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

CONDITIONS

Official Title

Biological Bank for Atrial Fibrillation and Stroke

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • History of atrial fibrillation (AF) or atrial tachycardia (AT)
  • Scheduled for electrophysiological exploration or AF ablation (for certain groups)
  • History of stroke
  • Age over 80 years with normal heart rhythm and no left atrial enlargement
  • Cryptogenic stroke or transient ischemic attack before age 50 with no AF history
Not Eligible

You will not qualify if you...

  • No history of atrial fibrillation
  • Patients who have not signed consent
  • Pregnant women (for certain groups)
  • Left atrial enlargement greater than 25 cm² or 34 m/m², ejection fraction below 50%
  • QRS duration longer than 90 ms on ECG
  • Cardiac diseases except hypertension and valvular disease
  • History of stroke or transient ischemic attack over age 50
  • History of atrial fibrillation in cryptogenic stroke group

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Service neurologie Centre hospitalier Fleyriat

Bourg-en-Bresse, France, 01000

Actively Recruiting

2

Service d'urgences Neurovasculaires - service de neurologie vasculaire , Hôpital Pierre Wertheimer

Bron, France, 69677

Actively Recruiting

3

Service de rythmologie, hôpital cardiologique Louis Pradel

Bron, France, 69677

Actively Recruiting

4

Service de médecine gériatrique Centre hospitalier Lyon Sud, Groupement hospitalier Sud

Pierre-Bénite, France, 69495

Actively Recruiting

5

Hôpital des charpennes

Villeurbanne, France, 69100

Actively Recruiting

Loading map...

Research Team

P

Philippe CHEVALIER, PU-PH

CONTACT

E

Elodie MOREL

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

5

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Biological Bank for Atrial Fibrillation and Stroke | DecenTrialz